Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

ZLAB

Zai Lab Limited ADR

Sep 20 • 04:00PM ET

21.85

Dollar change +0.76
Percentage change 3.60	%

Healthcare • Biotechnology • China • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: IBB SBIO PGJ FMED BBP DFEM DFAE BIB IBBQ SPGM

Index	-	P/E	-	EPS (ttm)	-3.07	Insider Own	0.59%	Shs Outstand	99.12M	Perf Week	6.53%
Market Cap	2.17B	Forward P/E	-	EPS next Y	-1.80	Insider Trans	-13.65%	Shs Float	98.53M	Perf Month	24.86%
Income	-298.33M	PEG	-	EPS next Q	-0.76	Inst Own	42.94%	Short Float	5.01%	Perf Quarter	17.66%
Sales	322.71M	P/S	6.71	EPS this Y	13.61%	Inst Trans	-2.02%	Short Ratio	8.52	Perf Half Y	26.67%
Book/sh	7.18	P/B	3.05	EPS next Y	39.88%	ROA	-28.50%	Short Interest	4.93M	Perf Year	-13.94%
Cash/sh	7.37	P/C	2.97	EPS next 5Y	-	ROE	-36.46%	52W Range	13.48 - 31.22	Perf YTD	-20.05%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.93%	ROI	-42.02%	52W High	-30.01%	Beta	1.06
Dividend TTM	-	Quick Ratio	3.29	Sales past 5Y	2095.12%	Gross Margin	62.95%	52W Low	62.09%	ATR (14)	0.87
Dividend Ex-Date	-	Current Ratio	3.46	EPS Y/Y TTM	24.90%	Oper. Margin	-109.67%	RSI (14)	69.13	Volatility	3.50% 4.36%
Employees	2175	Debt/Eq	0.12	Sales Y/Y TTM	28.16%	Profit Margin	-92.44%	Recom	1.13	Target Price	47.69
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	34.35%	Payout	-	Rel Volume	0.91	Prev Close	21.09
Sales Surprise	7.45%	EPS Surprise	-15.75%	Sales Q/Q	45.95%	Earnings	Aug 06 AMC	Avg Volume	578.88K	Price	21.85
SMA20	9.94%	SMA50	16.86%	SMA200	9.97%	Trades		Volume	524,487	Change	3.60%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-14-23	Initiated	Morgan Stanley	Overweight	$47.50
Aug-10-23	Initiated	Cantor Fitzgerald	Overweight	$70
Jan-21-22	Initiated	Macquarie	Outperform	$64
Oct-12-21	Initiated	Bernstein	Mkt Perform
Apr-28-20	Initiated	Goldman	Buy
Apr-15-20	Initiated	Guggenheim	Buy	$75
Jul-12-19	Initiated	BofA/Merrill	Buy
Jul-05-19	Initiated	Macquarie	Outperform
Jan-29-19	Initiated	Credit Suisse	Outperform
Nov-21-18	Initiated	Jefferies	Buy
Jun-21-18	Resumed	Leerink Partners	Outperform	$43
Feb-14-18	Upgrade	JP Morgan	Neutral → Overweight
Oct-16-17	Initiated	Leerink Partners	Outperform	$42
Oct-16-17	Initiated	JP Morgan	Neutral	$32

Show Previous Ratings

Sep-17-24 01:32PM	Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024 (Business Wire)
Aug-29-24 04:09PM	Zai Lab Limited (ZLAB): Top ADR Stock According to Hedge Funds (Insider Monkey)
Aug-27-24 08:30AM	Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024 (Business Wire)
Aug-22-24 07:30AM	Zai Lab Announces Participation in September Investor Conferences (Business Wire)
Aug-06-24 04:05PM	Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates (Business Wire) -8.06%
08:04AM	Loading…
Jul-26-24 08:04AM	Trade of the Day: Zai Lab (ZLAB) Stock Is a Possible Hidden Gem (InvestorPlace)
Jul-17-24 06:32AM	China NMPA approves Zai Lab-argenxs efgartigimod alfa for gMG (Pharmaceutical Technology)
Jul-16-24 12:30AM	argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China (GlobeNewswire)
12:15AM	Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China (Business Wire)
Jul-15-24 02:53PM	Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy (Business Wire)
Jul-10-24 07:30AM	Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024 (Business Wire)
Jun-27-24 07:00PM	Insider Selling: Chairperson & CEO Ying Du Sells Shares of Zai Lab Ltd (ZLAB) (GuruFocus.com)
Jun-11-24 04:05PM	Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D (Business Wire)
Jun-04-24 11:59AM	Qiming's Nisa Leung Made the 2024 Forbes Midas List (PR Newswire) +7.17%
May-27-24 09:09AM	Here's Why Zai Lab Limited (ZLAB) Fell in Q1 (Insider Monkey)
08:52AM	Loading…
May-23-24 08:52AM	Zai Lab doses first subject in Phase II plaque psoriasis treatment trial (Clinical Trials Arena) -5.46%
May-22-24 07:30AM	Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis (Business Wire)
May-20-24 06:31AM	Chinas NMPA approves Zai Labs XACDURO NDA for pneumonia (Pharmaceutical Technology) +7.42%
04:06AM	Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment (MT Newswires)
12:21AM	Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China (Business Wire)
May-17-24 02:36AM	Insider Sale: Chief Legal Officer of Zai Lab Ltd (ZLAB) Sells Shares (GuruFocus.com)
May-16-24 07:30AM	Zai Lab Announces Participation in May and June Investor Conferences (Business Wire)
May-14-24 08:41AM	Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator (MT Newswires)
07:30AM	Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China (Business Wire)
May-13-24 11:42AM	BMS and Zai Labs Augtyro gains NMPA approval to treat NSCLC (Pharmaceutical Technology) +7.17%
08:51AM	Zai Lab Says China Approves New Drug Application for Lung Cancer Treatment Augtyro (MT Newswires)
May-12-24 08:20PM	Zai Lab Announces Approval of AUGTYRO (repotrectinib) for Patients with ROS1-positive NSCLC by Chinas NMPA (Business Wire)
May-10-24 05:14PM	Zai Lab Limited (NASDAQ:ZLAB) Q1 2024 Earnings Call Transcript (Insider Monkey) +7.17%
May-09-24 01:17PM	Zai Lab's Shares Rise After Q1 Beat (MT Newswires) +26.80%
12:15PM	Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036 (PR Newswire)
07:29AM	Loading…
07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
May-08-24 09:57PM	ZLAB Stock Earnings: Zai Lab Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:05PM	Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates (Business Wire)
Apr-15-24 07:30AM	Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024 (Business Wire)
Apr-11-24 07:30AM	Zai Lab Statement on Executive Management Teams Agreement on Share Activities (Business Wire)
Apr-02-24 07:30AM	Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs (Business Wire)
Apr-01-24 07:30AM	Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic... (Business Wire)
Mar-27-24 09:29AM	Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer (Business Wire)
Mar-20-24 04:30PM	Shhh! 7 Small-Cap Stocks That Can Double by 2025 (InvestorPlace) -5.80%
Mar-19-24 07:01PM	Chief Legal Officer Edmondson Frazor Titus III Sells 10,000 Shares of Zai Lab Ltd (ZLAB) (GuruFocus.com)
Mar-13-24 07:05PM	Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors (Business Wire)
Mar-06-24 04:01PM	Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC) (Business Wire)
07:30AM	Zai Lab Announces Participation in March Investor Conference (Business Wire)
Mar-01-24 10:12AM	argenx SE (NASDAQ:ARGX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 08:51AM	Zai Lab Limited (NASDAQ:ZLAB) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 04:38PM	Zai Lab Ltd (ZLAB) Reports 25% Year-Over-Year Revenue Growth in Full-Year 2023 Financial Results (GuruFocus.com) +7.15% -7.51%
04:05PM	Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates (Business Wire)
Feb-25-24 09:32PM	Qiming Venture Partners Becomes a UN PRI Signatory (PR Newswire)
Jan-25-24 04:15PM	Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024 (Business Wire)
Jan-10-24 05:12PM	Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC (Business Wire)
Jan-04-24 07:02PM	Zai Lab Ltd Chairperson & CEO Ying Du Sells 8,380 Shares (GuruFocus.com)
Dec-22-23 12:00PM	What Makes Zai Lab Limited Unsponsored ADR (ZLAB) a New Buy Stock (Zacks)
Dec-19-23 07:30AM	Zai Lab Announces Participation in January Investor Conference (Business Wire)
Dec-13-23 08:53AM	Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA in China's National Reimbursement Drug List (GlobeNewswire) +11.85%
Dec-12-23 11:10PM	Zai Lab Announces the First Listing of VYVGART (efgartigimod alfa injection) and Other Updates in Chinas National Reimbursement Drug List (Business Wire)
Nov-23-23 09:42AM	14 Best Short-Term Stocks to Invest In (Insider Monkey)
Nov-09-23 02:39PM	Zai Lab Limited (NASDAQ:ZLAB) Q3 2023 Earnings Call Transcript (Insider Monkey) -6.16%
Nov-07-23 04:05PM	Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates (GlobeNewswire) +6.00%
Oct-26-23 07:30AM	Zai Lab Announces Participation in November Investor Conferences (GlobeNewswire)
Oct-18-23 07:30AM	Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023 (GlobeNewswire)
Oct-17-23 08:25AM	Ultragenyx (RARE) Surges 10.3%: Is This an Indication of Further Gains? (Zacks)
Oct-14-23 01:15PM	13 Stocks to Buy with Exponential Growth (Insider Monkey)
Sep-21-23 04:48PM	Betting Big: 3 Tech Stocks Primed for a Breakout (InvestorPlace) -5.55%
Sep-18-23 07:30AM	Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China (GlobeNewswire)
Sep-05-23 11:16AM	Why Shares of Zai Lab Limited Were Jumping on Tuesday (Motley Fool) +9.73%
09:23AM	Seagen's (SGEN) Late-Stage Cervical Cancer Study Meets Goals (Zacks)
Aug-31-23 09:16AM	Zai Lab (ZLAB) Up on Breakthrough Therapy Tag for Oncology Drug (Zacks)
Aug-30-23 07:30AM	Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China (GlobeNewswire) +11.39%
Aug-29-23 07:38AM	Zai Lab Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-10-23 10:12AM	Penn downgraded, Roblox upgraded: Wall Street's top analyst calls (The Fly)
Aug-07-23 04:05PM	Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire) -8.58%
Jul-28-23 03:57PM	12 Stocks with Biggest Upside Potential According to Analysts (Insider Monkey) +5.32%
Jul-20-23 07:30AM	Zai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023 (GlobeNewswire)
Jul-19-23 07:30AM	JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients (GlobeNewswire)
Jul-17-23 01:03AM	Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (GlobeNewswire)
Jul-14-23 07:30AM	Zai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer (GlobeNewswire)
Jul-10-23 07:30AM	Zai Lab Announces Acceptance by Chinas NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis (GlobeNewswire)
Jul-06-23 04:05PM	Zai Lab Announces Promotion of Yajing Chen to Chief Financial Officer (GlobeNewswire) -5.94%
Jun-30-23 11:20AM	UPDATE 2-Argenx's and Zai Lab's U.S. shares rise after muscle-weakening disease drug gets China's approval (Reuters)
09:22AM	Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China (GlobeNewswire)
Jun-28-23 07:30AM	Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by Chinas NMPA (GlobeNewswire)
Jun-12-23 08:56AM	Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation (Simply Wall St.)
Jun-07-23 11:05AM	Why Shares of Zai Lab Are Dropping Wednesday (Motley Fool) -14.55%
Jun-06-23 08:05AM	Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies (GlobeNewswire) -5.33%
Jun-01-23 04:03PM	Zai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting (GlobeNewswire) +8.18%
May-25-23 07:30AM	Zai Lab Announces Participation in June Investor Conferences (GlobeNewswire) -5.91%
May-24-23 08:01AM	12 Best Chinese Stocks to Buy Now (Insider Monkey)
May-22-23 11:11AM	Why Shares of Alibaba, PDD, and Zai Lab Are Rising Today (Motley Fool) +8.70%
May-18-23 07:30AM	Zai Lab Announces That Repotrectinib Granted Priority Review by Chinas NMPA (GlobeNewswire) -6.06%
May-15-23 02:57PM	Investors push Zai Lab (NASDAQ:ZLAB) 9.3% lower this week, company's increasing losses might be to blame (Simply Wall St.)
May-10-23 11:53AM	Mirati (MRTX) Q1 Earnings & Revenues Beat Estimates, Stock Up (Zacks) +6.08%
May-09-23 04:01PM	Zai Lab Announces First Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire)
May-03-23 09:58PM	Strength Seen in Inhibrx, Inc. (INBX): Can Its 9.9% Jump Turn into More Strength? (Zacks)
Apr-27-23 07:30AM	Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology (GlobeNewswire)
Apr-26-23 10:25AM	Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-20-23 07:30AM	Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023 (GlobeNewswire)
Apr-18-23 01:55PM	Revenues Not Telling The Story For Zai Lab Limited (NASDAQ:ZLAB) (Simply Wall St.)
Apr-14-23 03:32AM	Arvinas, Inc. (ARVN) Surges 7.6%: Is This an Indication of Further Gains? (Zacks)
Apr-11-23 08:03AM	Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting (GlobeNewswire) +11.38%
Mar-26-23 07:45AM	1 Hot Growth Stock to Buy Hand Over Fist Before It Blasts Off (Motley Fool)

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Reinhart Harald	Former Officer	Sep 19 '24	Proposed Sale	21.16	70,000	1,481,095		Sep 19 04:55 PM
GAYNOR RICHARD	Director	Sep 03 '24	Sale	19.50	2,500	48,750	46,568	Sep 05 04:13 PM
GAYNOR RICHARD	Director	Sep 03 '24	Proposed Sale	19.50	2,500	48,750		Sep 03 12:12 PM
Edmondson Frazor Titus III	Chief Legal Officer	Aug 19 '24	Sale	16.95	1,924	32,619	28,872	Aug 20 04:42 PM
Smiley Joshua L	See Remarks	Aug 16 '24	Sale	16.67	4,352	72,561	43,232	Aug 19 04:45 PM
Edmondson Frazor Titus III	Officer	Aug 19 '24	Proposed Sale	16.95	1,924	32,620		Aug 19 03:16 PM
Chen Yajing	Chief Financial Officer	Aug 15 '24	Sale	16.06	422	6,779	14,542	Aug 16 04:38 PM
Smiley Joshua L	Officer	Aug 16 '24	Proposed Sale	16.67	4,352	72,560		Aug 16 03:14 PM
Chen Yajing	Officer	Aug 15 '24	Proposed Sale	16.06	422	6,779		Aug 15 03:37 PM
Amado Rafael	See Remarks	Aug 12 '24	Sale	16.20	3,115	50,463	20,417	Aug 14 04:18 PM
Amado Rafael	Officer	Aug 12 '24	Proposed Sale	16.20	3,115	50,463		Aug 12 11:30 AM
Lis William	Director	Jul 01 '24	Sale	17.32	10,397	180,085	53,089	Jul 03 02:04 PM
Du Ying	Chairperson & CEO	Jul 01 '24	Sale	17.48	7,013	122,573	1,081,910	Jul 02 04:30 PM
Reinhart Harald	See Remarks	Jun 26 '24	Sale	17.90	7,431	133,022	62,619	Jun 27 04:09 PM
Edmondson Frazor Titus III	Chief Legal Officer	Jun 26 '24	Sale	17.90	5,062	90,615	25,946	Jun 27 04:09 PM
Du Ying	Chairperson & CEO	Jun 26 '24	Sale	17.90	23,939	428,532	1,142,833	Jun 27 04:08 PM
Chen Yajing	Chief Financial Officer	Jun 26 '24	Sale	17.90	2,154	38,559	13,714	Jun 27 04:08 PM
Edmondson Frazor Titus III	Chief Legal Officer	May 14 '24	Sale	21.33	10,000	213,346	16,408	May 16 04:52 PM
Smiley Joshua L	See Remarks	May 13 '24	Buy	21.40	3,000	64,200	31,684	May 15 04:03 PM
Smiley Joshua L	See Remarks	Apr 03 '24	Option Exercise	15.90	7,145	113,606	30,672	Apr 05 05:48 PM
Smiley Joshua L	See Remarks	Apr 04 '24	Sale	15.67	1,988	31,158	28,684	Apr 05 05:48 PM
Reinhart Harald	See Remarks	Apr 03 '24	Option Exercise	15.90	5,270	83,793	53,905	Apr 05 05:48 PM
Reinhart Harald	See Remarks	Apr 04 '24	Sale	15.67	2,105	32,992	51,800	Apr 05 05:48 PM
Edmondson Frazor Titus III	Chief Legal Officer	Apr 03 '24	Option Exercise	15.90	5,031	79,993	27,652	Apr 05 05:48 PM
Edmondson Frazor Titus III	Chief Legal Officer	Apr 04 '24	Sale	15.67	1,244	19,497	26,408	Apr 05 05:48 PM
Chen Yajing	Chief Financial Officer	Apr 03 '24	Option Exercise	15.90	2,500	39,750	10,463	Apr 05 05:47 PM
Chen Yajing	Chief Financial Officer	Apr 04 '24	Sale	15.67	845	13,244	9,618	Apr 05 05:47 PM
Amado Rafael	See Remarks	Apr 03 '24	Option Exercise	15.90	5,391	85,717	25,484	Apr 05 05:47 PM
Amado Rafael	See Remarks	Apr 04 '24	Sale	15.67	1,952	30,594	23,532	Apr 05 05:47 PM
Edmondson Frazor Titus III	Chief Legal Officer	Apr 01 '24	Option Exercise	16.72	3,501	58,537	23,506	Apr 03 09:54 PM
Edmondson Frazor Titus III	Chief Legal Officer	Apr 02 '24	Sale	16.15	885	14,294	22,621	Apr 03 09:54 PM
Reinhart Harald	See Remarks	Apr 01 '24	Option Exercise	16.72	4,348	72,699	50,408	Apr 03 09:45 PM
Reinhart Harald	See Remarks	Apr 02 '24	Sale	16.15	1,773	28,636	48,635	Apr 03 09:45 PM
Du Ying	Chairperson & CEO	Apr 01 '24	Option Exercise	16.72	14,200	237,424	1,113,759	Apr 03 09:44 PM
Du Ying	Chairperson & CEO	Apr 02 '24	Sale	16.15	5,787	93,466	1,107,972	Apr 03 09:44 PM
Chen Yajing	Chief Financial Officer	Apr 01 '24	Option Exercise	16.72	1,500	25,080	8,482	Apr 03 09:44 PM
Chen Yajing	Chief Financial Officer	Apr 02 '24	Sale	16.15	519	8,382	7,963	Apr 03 09:44 PM
Amado Rafael	See Remarks	Mar 15 '24	Sale	18.86	2,544	47,980	20,093	Mar 19 04:12 PM
Edmondson Frazor Titus III	Chief Legal Officer	Mar 15 '24	Sale	18.71	10,000	187,127	20,005	Mar 19 04:12 PM
Smiley Joshua L	See Remarks	Mar 01 '24	Buy	20.83	3,000	62,490	23,527	Mar 04 04:28 PM
Amado Rafael	See Remarks	Jan 02 '24	Sale	26.30	19,363	509,169	22,637	Jan 03 07:26 PM
Du Ying	Chairperson & CEO	Jan 03 '24	Sale	26.12	8,380	218,902	1,133,450	Jan 03 07:25 PM
Reinhart Harald	See Remarks	Jan 03 '24	Sale	26.12	4,803	125,464	46,060	Jan 03 07:25 PM
Edmondson Frazor Titus III	Chief Legal Officer	Jan 03 '24	Sale	26.12	4,803	125,464	30,005	Jan 03 07:25 PM
Smiley Joshua L	See Remarks	Dec 14 '23	Buy	29.90	4,000	119,600	20,527	Dec 18 05:08 PM
Smiley Joshua L	See Remarks	Nov 16 '23	Buy	26.93	5,000	134,650	16,527	Nov 16 06:04 PM
Chen Yajing	Chief Financial Officer	Nov 02 '23	Sale	25.23	165	4,163	6,982	Nov 03 04:44 PM

Open in Screener

JSPR

Jasper Therapeutics Inc

Sep 20 • 04:00PM ET

23.88

Dollar change -0.03
Percentage change -0.13	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

JSPR Jasper Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IWO VTWO IWC FESM AVSC CANC VTWG

Index	RUT	P/E	-	EPS (ttm)	-5.10	Insider Own	23.35%	Shs Outstand	15.11M	Perf Week	4.97%
Market Cap	360.83M	Forward P/E	-	EPS next Y	-4.15	Insider Trans	-0.05%	Shs Float	11.58M	Perf Month	26.89%
Income	-62.44M	PEG	-	EPS next Q	-1.07	Inst Own	77.42%	Short Float	17.29%	Perf Quarter	7.96%
Sales	0.00M	P/S	-	EPS this Y	32.50%	Inst Trans	5.01%	Short Ratio	10.08	Perf Half Y	-19.51%
Book/sh	6.64	P/B	3.60	EPS next Y	0.53%	ROA	-52.45%	Short Interest	2.00M	Perf Year	209.73%
Cash/sh	7.07	P/C	3.38	EPS next 5Y	-	ROE	-59.32%	52W Range	4.00 - 31.01	Perf YTD	202.66%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-61.45%	52W High	-22.99%	Beta	2.23
Dividend TTM	-	Quick Ratio	10.79	Sales past 5Y	0.00%	Gross Margin	-	52W Low	497.00%	ATR (14)	1.61
Dividend Ex-Date	-	Current Ratio	10.79	EPS Y/Y TTM	48.65%	Oper. Margin	0.00%	RSI (14)	69.09	Volatility	7.89% 7.90%
Employees	45	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.09	Target Price	71.62
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	33.91%	Payout	-	Rel Volume	2.06	Prev Close	23.91
Sales Surprise	-	EPS Surprise	10.89%	Sales Q/Q	-	Earnings	Aug 13 BMO	Avg Volume	198.53K	Price	23.88
SMA20	15.66%	SMA50	21.74%	SMA200	24.65%	Trades		Volume	409,755	Change	-0.13%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-09-24	Initiated	JMP Securities	Mkt Outperform	$70
Jul-08-24	Initiated	BTIG Research	Buy	$90
Jun-27-24	Initiated	Stifel	Buy	$86
May-06-24	Initiated	H.C. Wainwright	Buy	$65
Apr-03-24	Initiated	Evercore ISI	Outperform	$65
Mar-28-24	Initiated	RBC Capital Mkts	Outperform	$70
Mar-18-24	Initiated	TD Cowen	Outperform
Aug-11-23	Initiated	CapitalOne	Overweight	$7
Feb-28-22	Initiated	Cantor Fitzgerald	Overweight	$10
Nov-08-21	Initiated	Credit Suisse	Outperform	$15
Oct-21-21	Initiated	William Blair	Outperform
Oct-20-21	Initiated	BMO Capital Markets	Outperform	$19
Oct-13-21	Initiated	Oppenheimer	Outperform	$21

Show Previous Ratings

Sep-10-24 07:30AM	Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma (GlobeNewswire) +5.13%
Sep-04-24 04:30PM	Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-13-24 07:00AM	Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments (GlobeNewswire) +12.40%
Jun-19-24 08:00AM	Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors (GlobeNewswire)
Jun-17-24 04:30PM	Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit (GlobeNewswire)
08:00AM	Loading…
Jun-14-24 08:00AM	Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress (GlobeNewswire)
May-30-24 06:05PM	Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024 (GlobeNewswire) +7.72%
May-29-24 04:30PM	Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 01:53PM	JSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments (GlobeNewswire)
May-13-24 08:00AM	Jasper Therapeutics Announces Briquilimab Development Program in Asthma (GlobeNewswire)
May-07-24 04:30PM	Jasper Therapeutics to Present at Upcoming Investor Conferences in May (GlobeNewswire) -6.94%
12:00PM	Jasper Therapeutics (JSPR) Upgraded to Buy: Here's What You Should Know (Zacks)
Apr-02-24 04:30PM	Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -7.42%
Mar-22-24 08:50AM	Jasper Therapeutics (JSPR) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
04:30PM	Loading…
Mar-21-24 04:30PM	Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire) +8.01%
Mar-19-24 08:00AM	Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria (GlobeNewswire) +5.55%
Mar-15-24 08:00AM	New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia (GlobeNewswire)
Mar-14-24 12:00PM	Jasper Therapeutics, Inc. (JSPR) Is Up 24.77% in One Week: What You Should Know (Zacks) -9.11%
Mar-06-24 12:53PM	JSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +8.21%
08:50AM	Here's Why Momentum in Jasper Therapeutics, Inc. (JSPR) Should Keep going (Zacks)
Mar-04-24 07:30AM	Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Feb-26-24 04:30PM	Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference (GlobeNewswire)
Feb-23-24 08:00AM	Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting (GlobeNewswire)
Feb-19-24 08:50AM	Here's What Could Help Jasper Therapeutics, Inc. (JSPR) Maintain Its Recent Price Strength (Zacks)
Feb-07-24 08:00AM	Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference (GlobeNewswire) +18.00%
Feb-06-24 08:59AM	Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock (GlobeNewswire) +14.52%
Feb-05-24 08:00AM	Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting (GlobeNewswire) +7.65%
Feb-02-24 08:00AM	Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-24-24 12:14PM	Jasper Therapeutics (JSPR) Surges 110% in a Month: Here's Why (Zacks)
08:30AM	Loading…
Jan-05-24 08:30AM	Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones (GlobeNewswire)
Jan-02-24 08:00AM	Jasper Therapeutics, Inc. Announces Reverse Stock Split (GlobeNewswire) -13.74%
Dec-18-23 04:30PM	Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +12.11%
Dec-10-23 11:00AM	Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023 (GlobeNewswire)
Nov-30-23 08:00AM	Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria (GlobeNewswire)
Nov-09-23 09:48AM	Jasper Therapeutics Inc (JSPR) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com) -8.08%
08:00AM	Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-08-23 04:30PM	Jasper Therapeutics to Participate at Upcoming Medical and Investor Conferences (GlobeNewswire)
Nov-02-23 09:00AM	Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023 (GlobeNewswire)
Nov-01-23 08:00AM	Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors (GlobeNewswire)
Oct-09-23 08:30AM	Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023 (GlobeNewswire) +16.25%
08:00AM	Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria (GlobeNewswire)
Sep-25-23 08:00AM	Jasper Therapeutics Appoints Herb Cross as Chief Financial Officer (GlobeNewswire) -8.97%
Sep-21-23 08:00AM	Jasper Therapeutics to Present New Positive Data on Briquilimab Conditioning in Patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific Symposium (GlobeNewswire)
Sep-15-23 08:00AM	Jasper Therapeutics to Present at the Cantor Fitzgerald 2023 Global Healthcare Conference (GlobeNewswire) +10.96%
Aug-11-23 04:05PM	Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-04-23 04:51PM	Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-02-23 08:00AM	Jasper Therapeutics Strengthens Management Team with Key Appointments (GlobeNewswire)
Jun-22-23 08:00AM	Jasper Therapeutics Announces First Patient Dosed in a Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome (GlobeNewswire)
Jun-20-23 08:00AM	Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors (GlobeNewswire)
Jun-13-23 08:00AM	Jasper Therapeutics Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer (GlobeNewswire) +6.17%
May-12-23 04:05PM	Jasper Therapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) +5.37%
May-10-23 08:00AM	Jasper Therapeutics Announces Appointment of Stephen J. Galli, M.D. to Scientific Advisory Board (GlobeNewswire)
Apr-13-23 08:00AM	Jasper Therapeutics Announces Appointment of Matthew Ford as Vice President, Human Resources (GlobeNewswire)
Apr-10-23 04:05PM	Jasper Therapeutics Appoints David Hinds as Senior Vice President, Development Operations (GlobeNewswire)
Mar-31-23 08:00AM	Jasper Therapeutics to Present at Cantor Fitzgeralds The Future of Oncology Virtual Symposium (GlobeNewswire)
Mar-23-23 08:00AM	Jasper Therapeutics Appoints Daniel Adelman, M.D., as Acting Chief Medical Officer (GlobeNewswire)
Mar-09-23 08:00AM	Jasper Therapeutics to Present at Upcoming Conferences (GlobeNewswire) -7.00%
Mar-08-23 04:05PM	Jasper Therapeutics Reports Fiscal 2022 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-17-23 08:20AM	Jasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of Directors (GlobeNewswire)
08:10AM	Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR (GlobeNewswire)
08:00AM	Jasper Therapeutics Presents Data Supporting Ongoing Development of Briquilimab, its c-Kit Targeting Antibody, at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR (GlobeNewswire)
Feb-16-23 04:05PM	Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Sickle Cell Disease Patients (GlobeNewswire)
Feb-03-23 04:05PM	Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.43%
Jan-30-23 08:00AM	Jasper Therapeutics to Host Investor Conference Call and Webcast on January 31, 2023 (GlobeNewswire)
Jan-27-23 01:10PM	Jasper Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Jan-25-23 08:00AM	Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock (GlobeNewswire) +9.47%
Jan-24-23 04:25PM	Jasper Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) -5.59%
Jan-13-23 08:00AM	Jasper Therapeutics Announces New Positive Briquilimab Data to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (GlobeNewswire) +7.88%
Jan-10-23 08:00AM	Jasper Therapeutics Announces Development Prioritization of Briquilimab in Chronic Diseases, Including Urticaria and Lower-Risk MDS, and Stem Cell Transplant for Sickle Cell Disease and Other Rare Diseases (GlobeNewswire)
Jan-04-23 08:00AM	Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as a Conditioning Treatment for Patients Prior to Receiving a Stem Cell Transplant (GlobeNewswire) -21.90%
Jan-03-23 08:00AM	Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia (GlobeNewswire) +467.41%
Nov-10-22 04:05PM	Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
Sep-26-22 08:00AM	Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual Meeting (GlobeNewswire)
Sep-23-22 08:00AM	Jasper Therapeutics to Present at Upcoming Conferences (GlobeNewswire) -13.49%
Sep-15-22 08:00AM	Jasper Therapeutics Announces FDA Fast Track Designation for JSP191, a novel monoclonal antibody targeting CD117, in the treatment of patients with severe combined immunodeficiency (SCID) undergoing allogeneic hematopoietic stem cell transplant (GlobeNewswire)
Aug-12-22 04:05PM	Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire) -7.08%
Jun-23-22 04:05PM	Jasper Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium (GlobeNewswire) +17.34% +15.27%
Jun-20-22 10:59AM	Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jun-07-22 08:00AM	Jasper Therapeutics to Participate in the William Blair 42nd Annual Growth Stock Conference (GlobeNewswire) -5.70%
Jun-06-22 08:00AM	Jasper Therapeutics Announces Annual Virtual Stockholders Meeting to be Held on Thursday, June 23, 2022 (GlobeNewswire)
May-27-22 08:00AM	After a record-breaking decade, biotech is discovering what hard times feel like (American City Business Journals)
May-17-22 08:00AM	Jasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi Anemia (GlobeNewswire)
May-12-22 04:05PM	Jasper Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-28-22 08:00AM	Jasper Therapeutics Announces Plans for Registrational Study of JSP191 in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation after Type C FDA Meeting (GlobeNewswire)
Apr-26-22 04:05PM	Jasper Therapeutics Announces Updated Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation (GlobeNewswire)
Apr-22-22 08:00AM	Jasper Therapeutics to Host In-Person Key Opinion Leader Webinar on Transforming Hematopoietic Stem Cell Therapies (GlobeNewswire)
Mar-31-22 08:00AM	Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting (GlobeNewswire) +5.97%
Mar-25-22 07:30PM	Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-21-22 08:30AM	Jasper Therapeutics Announces Management Changes to Strengthen Leadership Team (GlobeNewswire)
Mar-18-22 04:05PM	Jasper Therapeutics Announces Fiscal 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-10-22 08:00AM	Jasper Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire) -7.96%
Feb-28-22 08:00AM	Jasper Therapeutics Announces Appointment of Ronald Martell as Chief Executive Officer (GlobeNewswire)
Feb-24-22 05:19PM	Jasper Therapeutics Announces JSP191 Phase 1b MDS/AML Late Breaking Data Presentation at the 2022 Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Feb-02-22 01:38PM	Grace Capital Buys Vanguard Consumer Discretionary ETF, Tesla Inc, Jasper Therapeutics Inc, ... (GuruFocus.com) -12.07%
Dec-08-21 11:15AM	Billionaire Ken Griffin Goes Big on These 3 Strong Buy Stocks (TipRanks) +6.00%
08:30AM	Jasper Therapeutics to Present Data on JSP191 Conditioning in SCID patients at the 2021 American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-20-21 08:21AM	Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth (Simply Wall St.)
Nov-12-21 04:05PM	Jasper Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Nov-09-21 08:00AM	Jasper Therapeutics Announces Research Collaboration with AVROBIO to Evaluate JSP191 as Conditioning Agent in Clinical Studies of Ex Vivo Lentiviral Gene Therapy (GlobeNewswire)

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mahal Jeetinder Singh	Chief Operating Officer	Sep 12 '24	Option Exercise	7.10	900	6,390	25,909	Sep 12 05:19 PM
Mahal Jeetinder Singh	Chief Operating Officer	Sep 12 '24	Sale	21.23	900	19,104	25,009	Sep 12 05:19 PM
Jeetinder Singh Mahal	Executive Officer	Sep 12 '24	Proposed Sale	20.66	900	18,590		Sep 12 05:18 PM
Mahal Jeetinder Singh	Chief Operating Officer	Jun 12 '24	Option Exercise	7.10	900	6,390	25,909	Jun 12 09:40 PM
Mahal Jeetinder Singh	Chief Operating Officer	Jun 12 '24	Sale	24.16	900	21,740	25,009	Jun 12 09:40 PM
Mahal Jeetinder Singh	Chief Operating Officer	Mar 12 '24	Option Exercise	7.10	900	6,390	25,909	Mar 12 09:33 PM
Mahal Jeetinder Singh	Chief Operating Officer	Mar 12 '24	Sale	26.44	900	23,792	25,009	Mar 12 09:33 PM
Carlyle Group Inc.	Former 10% Owner	Feb 08 '24	Buy	12.95	190,000	2,460,500	1,066,189	Feb 12 06:23 PM
Velan Capital Investment Manag	10% Owner	Feb 08 '24	Buy	12.95	350,000	4,532,500	1,188,500	Feb 09 08:40 PM
WIGGANS THOMAS G	Director	Nov 28 '23	Buy	0.65	10,000	6,486	50,000	Nov 30 04:05 PM
WIGGANS THOMAS G	Director	Nov 21 '23	Buy	0.64	10,000	6,383	40,000	Nov 22 04:06 PM
WIGGANS THOMAS G	Director	Nov 20 '23	Buy	0.63	10,000	6,309	30,000	Nov 20 08:14 PM
WIGGANS THOMAS G	Director	Nov 17 '23	Buy	0.60	10,000	5,966	20,000	Nov 20 08:14 PM
WIGGANS THOMAS G	Director	Nov 16 '23	Buy	0.60	10,000	5,965	10,000	Nov 20 08:14 PM
Lis William	Director	Oct 13 '23	Sale	0.85	7,965	6,777	53,521	Oct 13 06:56 PM

ZLAB

Zai Lab Limited ADR

JSPR

Jasper Therapeutics Inc

Upgrade your FINVIZ experience